BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The BioCalendar - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:The BioCalendar
X-ORIGINAL-URL:https://thebiocalendar.com
X-WR-CALDESC:Events for The BioCalendar
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260511
DTEND;VALUE=DATE:20260516
DTSTAMP:20260530T050124
CREATED:20251206T101044Z
LAST-MODIFIED:20251206T101044Z
UID:9623-1778457600-1778889599@thebiocalendar.com
SUMMARY:ASGCT Annual Meeting
DESCRIPTION:The ASGCT Annual Meeting is the leading global event for professionals in gene and cell therapy\, hosted by the American Society of Gene + Cell Therapy (ASGCT) to showcase cutting-edge research\, new technologies\, and clinical applications\, offering crucial networking for scientists\, industry leaders\, and clinicians to advance treatments for human diseases. It features expert presentations\, novel abstract presentations\, workshops\, and exhibitions from companies in the cell and gene therapy ecosystem.
URL:https://thebiocalendar.com/event/asgct-annual-meeting/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Academic Research,Networking,Presentation
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260511
DTEND;VALUE=DATE:20260516
DTSTAMP:20260530T050124
CREATED:20251206T101440Z
LAST-MODIFIED:20260116T121409Z
UID:9625-1778457600-1778889599@thebiocalendar.com
SUMMARY:PEGS Boston
DESCRIPTION:The PEGS Boston Summit is where the future of biologics takes shape. For over 20 years\, PEGS is the go-to event for protein and antibody engineering\, drug development\, immunotherapy\, radiotherapy\, and AI/ML-driven biologics research. New in 2026: a dedicated focus on peptides\, spotlighting their therapeutic power\, design innovations\, and expanding role in drug discovery. \nWith 350+ presentations\, breakout sessions\, and interactive training seminars\, PEGS delivers the insights and connections you need to stay ahead. The exhibit hall buzzes with top technology and service providers\, giving you a front-row seat to the tools transforming the industry. \nDon’t just follow the science – be part of it. Join us at the 2026 PEGS Boston Summit and connect with the leaders shaping what’s next in biologics and beyond.
URL:https://thebiocalendar.com/event/pegs-boston-3/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Featured,Summit
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2025/12/pegs2026-scaled.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260511T080000
DTEND;TZID=America/Los_Angeles:20260514T170000
DTSTAMP:20260530T050124
CREATED:20251206T100827Z
LAST-MODIFIED:20251206T100827Z
UID:9622-1778486400-1778778000@thebiocalendar.com
SUMMARY:AAPS National Biotechnology Conference
DESCRIPTION:The AAPS National Biotechnology Conference (NBC) is a premier annual event by the American Association of Pharmaceutical Scientists (AAPS) for leaders in pharma and biotech to explore cutting-edge science in biologics\, advanced therapies\, and innovative drug development\, focusing on new modalities like CAR-T\, gene therapies\, and AI in drug discovery\, bridging research from lab to patient. It features scientific sessions\, poster presentations\, and networking opportunities\, addressing challenges in formulation\, bioanalysis\, manufacturing\, and translational science for complex drugs
URL:https://thebiocalendar.com/event/aaps-national-biotechnology-conference/
LOCATION:San Diego\, San Diego\, CA\, United States
CATEGORIES:Academic Research,Summit,Symposium
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260512
DTEND;VALUE=DATE:20260515
DTSTAMP:20260530T050124
CREATED:20260330T202508Z
LAST-MODIFIED:20260330T202508Z
UID:10116-1778544000-1778803199@thebiocalendar.com
SUMMARY:Fierce Biotech Week
DESCRIPTION:Be in the Room Where Decisions Are Made \n\n\n\n\n\n\n\n\nFierce Biotech Week attracts senior leaders across biotech and pharma\, including: \n\n\nC-suite executives and founders \n\n\nHeads of R&D and Drug Development \n\n\nClinical & TMF leadership \n\n\nBD&L and corporate strategy teams \n\n\nPR & Communications executives \n\n\nStrategic outsourcing partners \n\n\nThis is not a spectator audience. It’s a room of decision-makers.
URL:https://thebiocalendar.com/event/fierce-biotech-week-2/
LOCATION:Boston\, MA\, 02210\, United States
CATEGORIES:Summit
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T080000
DTEND;TZID=America/Los_Angeles:20260512T103000
DTSTAMP:20260530T050124
CREATED:20260504T223323Z
LAST-MODIFIED:20260504T223323Z
UID:10345-1778572800-1778581800@thebiocalendar.com
SUMMARY:Bay Area Biotech Forum
DESCRIPTION:From research to regulation\, the biotech industry is taking a hit\, but drug-development companies continue to press forward\, moving important discoveries from the lab bench to the patient bedside. \nThe program will begin with a talk with Ultragenyx CEO Emil Kakkis\, the scientist behind the first treatment for an ultra-rare genetic disease\, and Ryan Dant\, the first patient. Moderated by Ron Leuty. \nOur panel will explore the macro issues and micro decisions shaping the Bay Area biotech ecosystem\, along with the opportunities ahead.
URL:https://thebiocalendar.com/event/bay-area-biotech-forum-2/
LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States
CATEGORIES:Forum
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T110000
DTEND;TZID=America/Los_Angeles:20260512T120000
DTSTAMP:20260530T050124
CREATED:20260414T133825Z
LAST-MODIFIED:20260414T133825Z
UID:10194-1778583600-1778587200@thebiocalendar.com
SUMMARY:Applying AI to Study Simulation: From Design to Analysis
DESCRIPTION:AI is making it possible to simulate clinical trials before they begin using realistic synthetic patient cohorts built from real-world data. \nIn this session\, you’ll see how these simulations compare to actual Phase 2 and Phase 3 trial data\, and how teams are using them to test protocols\, reduce risk\, and improve study design faster. \nWe’ll also explore how TrialKit brings these capabilities into a single platform for simulation\, analysis\, and execution. \nYou’ll learn:\n– How synthetic patient cohorts are created and validated\n– How to simulate and refine trials before enrolling patients\n– Key considerations for applying AI in clinical research
URL:https://thebiocalendar.com/event/applying-ai-to-study-simulation-from-design-to-analysis/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Crucial-Data-eBlast-700x200-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T110000
DTEND;TZID=America/Los_Angeles:20260512T120000
DTSTAMP:20260530T050124
CREATED:20260417T125535Z
LAST-MODIFIED:20260417T125535Z
UID:10222-1778583600-1778587200@thebiocalendar.com
SUMMARY:Distributed Manufacturing for CGT: Rent\, Lease\, or Buy in an Era of Overcapacity?
DESCRIPTION:As cell and gene therapy companies navigate the 2026 landscape marked by manufacturing overcapacity\, a strategic question is no longer if to outsource\, but how.  \nFor leaders across MSAT\, CMC\, and technical operations\, the choice between renting\, leasing\, or building distributed manufacturing capabilities has direct implications for speed to clinic\, capital efficiency\, and long-term scalability. Critically\, many organizations still face a persistent gap in generating high-quality IND-enabling material early\, an issue that can delay clinical entry and jeopardize key funding milestones.  \nIn this Cell & Gene Live\, Chief Editor Erin Harris will be joined by Sugu Patro\, Ph.D.\, SVP Global Process Development\, at Kite Pharma and Emily Moran\, Founder and Principal of 3LB Consulting\, who will unpack what biotech teams should prioritize when evaluating partners in an overcapacity market\, how to align early manufacturing strategy with clinical and financial goals. They will also share lessons to be drawn from Kite’s in-house expertise to build more resilient\, future-ready manufacturing models.
URL:https://thebiocalendar.com/event/distributed-manufacturing-for-cgt-rent-lease-or-buy-in-an-era-of-overcapacity/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/26_05_CGL_LinkedIn_1280x720.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260512T130000
DTEND;TZID=America/Los_Angeles:20260512T140000
DTSTAMP:20260530T050124
CREATED:20260413T161457Z
LAST-MODIFIED:20260413T161458Z
UID:10190-1778590800-1778594400@thebiocalendar.com
SUMMARY:Don’t Sacrifice Compliance: Strategies for Audit-Ready System Integrations
DESCRIPTION:Discover how modern integration strategies are enabling companies to bridge critical systems\, streamline data flow\, and maintain regulatory confidence that supports innovation and compliance\, so your systems evolve as fast as your business.
URL:https://thebiocalendar.com/event/dont-sacrifice-compliance-strategies-for-audit-ready-system-integrations/
ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-12-26-Blue-Mountain-Reg-1920x250-rev.png
END:VEVENT
END:VCALENDAR